February 27, 2023
Inebilizumab for Treating Neuromyelitis Optical Spectrum Disorder
Inebilizumab therapy was determined to be effective for patients with prior exposure to rituximab; however, the majority of these patients experienced infections, increasing the need for vigilance. Neuromyelitis optica spectrum disorder (NMOSD) is a chronic and rare autoimmune inflammatory disorder affecting the central nervous system (CNS). NMOSD is characterized by repeated attacks of transverse myelitis,...
Relationship Between Life Quality and Disability Progression in NMOSD Patients
The quality of life of NMOSD patients corresponds to their degree of disability and can be improved with early interventions for preventing relapse. Neuromyelitis optical spectrum disorder (NMOSD) is a rare autoimmune disorder involving the spinal cord and optic nerves. There is a consistent and strong association between the quality of life (QoL) and disability...
Therapeutic Perspectives on Neuromyelitis Optica Spectrum Disorder
Therapeutic strategies for neuromyelitis optica spectrum disorder target pathogenic mechanisms of the disease and aim to restore the blood–brain barrier and enhance immune tolerance. Potential therapeutic strategies for neuromyelitis optica spectrum disorder (NMOSD) are based on targeting the B cell complement cascade system, and IL-6R. These strategies include restoration of the blood–brain barrier (BBB) and...